Track Keros Therapeutics, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Keros Therapeutics, Inc. KROS · Stock Open Keros Therapeutics, Inc. in new tab

10.30 USD
P/E
4.61
EPS
-2.32
P/B
0.68
ROE
-12.56
Beta
1.19
Target Price
19.83 USD
Loading chart...
Key Metrics
Earnings dateMarch 3, 2027
P/E4.61
EPS-2.32
Book Value14.07
Price to Book0.68
Debt/Equity5.41
% Insiders4.005%
Growth
Revenue Growth1.81%
Estimates
Forward P/E-1.44
Forward EPS-6.62
Target Mean Price19.83

DCF valuation

Model fair value for Keros Therapeutics, Inc. (KROS)
Result
Sign in to run the valuation for KROS.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
6 analysts · consensus Buy · mean target 19.83 USD (low 16.00, high 25.00) · as of 12 Nov 2026
Low 16.00
Mean 19.83
High 25.00
Price 10.30
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Keros Therapeutics, Inc. Logo Keros Therapeutics, Inc. Analysis (KROS)

United States Health Care Official Website Stock

Is Keros Therapeutics, Inc. a good investment? Keros Therapeutics, Inc. (KROS) is currently trading at 10.30 USD. Market analysts have a consensus price target of 19.83 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 4.61. This relatively low multiple may signal that Keros Therapeutics, Inc. is undervalued compared to historical market norms.

Earnings Schedule: Keros Therapeutics, Inc. is expected to release its next earnings report on March 3, 2027. The market consensus estimate for Forward EPS is -6.62.

Investor FAQ

Does Keros Therapeutics, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Keros Therapeutics, Inc.?

Keros Therapeutics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 3, 2027. The company currently has a trailing EPS of -2.32.

Company Profile

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept; and Takeda Pharmaceuticals U.S.A., Inc. to develop, manufacture, and commercialize elritercept and certain derivative compounds. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Exchange Ticker
NMS (United States) KROS
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion